NICE technology appraisal guidance
Issued: August 2012
TA263

Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer

This is an extract from the guidance. The complete guidance is available at guidance.nice.org.uk/ta263

1 Guidance

1.1 Bevacizumab in combination with capecitabine is not recommended within its marketing authorisation for the first-line treatment of metastatic breast cancer, that is, when treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate, or when taxanes or anthracyclines have been used as part of adjuvant treatment within the past 12 months.

1.2 People currently receiving bevacizumab in combination with capecitabine that is not recommended according to 1.1 should have the option to continue treatment until they and their clinician consider it appropriate to stop.